ROLE OF NEUROHUMORAL ACTIVATION IN THE DEVELOPMENT OF HYPERTENSION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- Authors: Selezneva E.1, Zhdanova T.1
-
Affiliations:
- Ural State Medical University
- Issue: Vol 26, No 2 (2015)
- Pages: 5-8
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116125
- ID: 116125
Cite item
Open Access
Access granted
Abstract
Chronic obstructive pulmonary disease is presently considered as a disease of the airways and lung with systemic manifestations. The latter include cardiovascular events, particularly hypertension that may be caused by hypoxemia, systemic inflammation, systemic oxidative stress, and neurohumoral activation.
Full Text
About the authors
E. Selezneva
Ural State Medical University
Email: selezneva.elena.1989@mail.ru
T. Zhdanova
Ural State Medical UniversityProfessor
References
- Sin D., Wu L., Man S. The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of theliterature // Chest. - 2005; 127 (6): 1952-9.
- World Health Organization. Constitution of the World Health Organization. 2006. http //apps.who.int/gb/bd/PDF/bd47/EN/constitution-en.pdf
- Cazzola M., Puxeddu E., Bettoncelli G. et al. The prevalence of asthma and COPD in Italy: a practice-based study // Respir. Med. - 2011; 105: 386-91.
- Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е. и др. Эпидемиология артериальной гипертонии в России. Результаты Федерального мониторинга 2003-2010гг. // Кардиоваскулярная терапия и профилактика. - 2011; 1: 9-13.
- Curkendall S., DeLuise C., Jones J. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients // Ann. Epidemiol. - 2006; 16: 63-70.
- Fabbri L., Luppi F., Beghe B. et al. Complex chronic comorbidities of COPD // Eur. Respir. J. - 2008; 31: 204-12.
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for thediagnosis, management and prevention of chronic obstructive pulmonary disease.NHLBI // WHO workshop repot Updated 2013. www.goldcopd.com
- Steckelings U., Unger T. The renin-angiotensin-aldosterone system; in Mancia G, Grassi G, Kjeldsen S. Manual of Hypertension of The European Society of Hypertension // Abingdon, Informa HealthCare. - 2008; 14: 110-6.
- Gan W., Man S., Senthilselvan A. et al. The association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis // Thorax. - 2004; 59: 574-80.
- Touyz R. Reactive oxygen species in vascular biology: role in arterial hypertension // Expert Rev. Cardiovasc. Ther. - 2003; 1: 91-106.
- Lemarie C., Esposito B., Tedgui A. et al. Pressure-induced vascularactivation of nuclear factor-kappaB: role in cell survival // Circ. Res. - 2003; 93: 207-12.
- Venugopal S., Devaraj S., Jialal I. Effect of C-reactive protein on vascularcells: evidence for a proinflammatory, proatherogenic role // Curr. Opin. Nephrol. Hypertens. - 2005; 14: 33-7.
- Bellocchia M., Masoero M., Ciuffreda A. Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Turin, Italy Multidisciplinary Respiratory Medicine, 2013.
Supplementary files
